De Sisti A, Tonet J, Barakett N, Lacotte J, Leclercq J F, Frank R
Rhythmology Unit, Cardiology Institute, Pitie-Salpetriere Hospital, Paris 75015, France.
Europace. 2007 Jun;9(6):401-6. doi: 10.1093/europace/eum031. Epub 2007 Apr 7.
Within the last several years, transvenous cryo-ablation has become an alternative method to perform ablation of the slow-pathway. This study evaluated the acute and long-term safety and effectiveness of atrio-ventricular nodal re-entrant tachycardia (AVNRT) cryo-ablation.
The first 69 consecutive patients with AVNRT (60 slow-fast, 4 fast-slow, and 5 slow-slow) who underwent slow-pathway cryo-ablation were included. Mean age was 37 +/- 15, body weight 68 +/- 14 kg, symptom duration 125 +/- 104 months, and number of ineffective antiarrhythmic (AA) drugs 1.8 +/- 1.4. A 7 Fr cryo-catheter (Cryocath(A)) was used, with initially 4-mm-tip and later with 6-mm-tip electrode. Cryo-mapping (n = 7.9 +/- 8.4 per pt) was performed at the temperature of -30 degrees C to test the effect on the target ablation site. Successful cryo-mapping was defined as abolition of nodal conduction jump or AV nodal refractory period prolongation. Cryo-ablation (n = 5.1 +/- 4.9 per pt) was then applied by freezing to -75 degrees C for 4 min in duration if no AV-block occurred. Acute procedural success (defined as AVNRT non-inducibility) after the first cryo-ablation attempt was achieved in 60/69 patients (87%). During cryo-ablation, inadvertent transient AV-block was encountered in 14 patients (five I AV-block and nine II-III AV-block). A mid-septal target site was the only variable correlated with inadvertent AV-block occurrence during cryo-ablation (P < 0.02). Long-term clinical success after cryo-ablation was globally achieved in 56/66 (85%) with a mean follow-up of 18 +/- 9 months (3 pts dropped-out). After the first procedure, 41/66 (62%) had no relapse, eight had a dramatic reduction in AVNRT duration-frequency and considered themselves cured, and five needed previously ineffective AA (with no relapse in three, drastic reduction in AVNRT duration-frequency in two). The five last patients needed one or more procedures, after which one had no recurrence and one had reduction in duration-frequency. Absence of recurrence after the first procedure was positively correlated with 6-mm-tip cryo-catheter use (<0.001) and negatively with acute procedural success (<0.001). At multivariate analysis, both were independently significant (<0.04 and <0.008, respectively). Long-term clinical success was correlated only with 6-mm-tip cryo-catheter use (<0.001).
Slow pathway cryo-ablation is associated with an acute success but a higher recurrence rate. A 6-mm-tip cryo-catheter seems to assure during cryo-ablation a large acute and long-term success. AV-block seems non-guaranteed by a negative cryo-mapping, stressing on need of a careful surveillance. Nevertheless, the theoretical advantage of avoiding the risk of permanent AV-block when compared with radiofrequency needs larger series to be demonstrated.
在过去几年中,经静脉冷冻消融已成为一种用于慢径路消融的替代方法。本研究评估了房室结折返性心动过速(AVNRT)冷冻消融的急性和长期安全性及有效性。
纳入连续69例接受慢径路冷冻消融的AVNRT患者(60例慢快型、4例快慢型和5例慢慢型)。平均年龄37±15岁,体重68±14kg,症状持续时间125±104个月,无效抗心律失常药物数量1.8±1.4种。使用7Fr冷冻导管(Cryocath(A)),最初为4mm尖端电极,后来为6mm尖端电极。在-30℃温度下进行冷冻标测(每位患者7.9±8.4次)以测试对目标消融部位的影响。成功的冷冻标测定义为结性传导跳跃消失或房室结不应期延长。如果未发生房室传导阻滞,则通过冷冻至-75℃持续4分钟进行冷冻消融(每位患者5.1±4.9次)。首次冷冻消融尝试后的急性手术成功率(定义为AVNRT不能诱发)在60/69例患者(87%)中实现。在冷冻消融期间,14例患者出现无意的短暂房室传导阻滞(5例一度房室传导阻滞和9例二度至三度房室传导阻滞)。中间隔目标部位是与冷冻消融期间无意的房室传导阻滞发生相关的唯一变量(P<0.02)。冷冻消融后的长期临床成功率在56/66例(85%)患者中总体实现,平均随访18±9个月(3例失访)。首次手术后,41/66例(62%)无复发,8例AVNRT持续时间-频率显著降低并认为已治愈,5例需要先前无效的抗心律失常药物(3例无复发,2例AVNRT持续时间-频率大幅降低)。最后5例患者需要进行一次或多次手术,之后1例无复发,1例持续时间-频率降低。首次手术后无复发与使用6mm尖端冷冻导管呈正相关(<0.001),与急性手术成功率呈负相关(<0.001)。在多变量分析中,两者均具有独立显著性(分别为<0.04和<0.008)。长期临床成功率仅与使用6mm尖端冷冻导管相关(<0.001)。
慢径路冷冻消融具有急性成功率,但复发率较高。6mm尖端冷冻导管似乎能确保冷冻消融期间较高的急性和长期成功率。阴性冷冻标测似乎不能保证不发生房室传导阻滞,强调需要仔细监测。然而,与射频相比,避免永久性房室传导阻滞风险的理论优势需要更大样本量来证实。